Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Corium, Gurnet Point Sell CDMO, Raise $100m
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
